Loncastuximab Tesirine is named as a drug or biological intervention in 2 clinical trials in our UK, USA and China trial registers, none of which are currently recruiting. The lead sponsor is ADC Therapeutics S.A.. Registered phases: Phase 3 and Phase 1. Conditions studied include Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; B-Cell Non-Hodgkin Lymphoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma |
Phase 3 | Active, closed |
| NCT04970901 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (ClinicalTrials.gov ↗) B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Relapsed Diffuse Large B-Cell Lymphoma | 1 |
| Refractory Diffuse Large B-Cell Lymphoma | 1 |
| B-Cell Non-Hodgkin Lymphoma | 1 |
| Relapsed B-Cell Non-Hodgkin Lymphoma | 1 |
| Refractory B-Cell Non-Hodgkin Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| ADC Therapeutics S.A. | 2 |
| Register | Loncastuximab Tesirine trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Loncastuximab Tesirine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Loncastuximab Tesirine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.